BVX vs. IMM, GENF, SNG, ROQ, BSFA, VAL, DEST, APTA, NSCI, and IXI
Should you be buying BiVictriX Therapeutics stock or one of its competitors? The main competitors of BiVictriX Therapeutics include ImmuPharma (IMM), Genflow Biosciences (GENF), Synairgen (SNG), Roquefort Therapeutics (ROQ), BSF Enterprise (BSFA), ValiRx (VAL), Destiny Pharma (DEST), Aptamer Group (APTA), NetScientific (NSCI), and IXICO (IXI). These companies are all part of the "biotechnology" industry.
BiVictriX Therapeutics (LON:BVX) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking and institutional ownership.
BiVictriX Therapeutics' return on equity of -59.06% beat ImmuPharma's return on equity.
BiVictriX Therapeutics has a beta of -0.61, meaning that its share price is 161% less volatile than the S&P 500. Comparatively, ImmuPharma has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.
34.8% of BiVictriX Therapeutics shares are held by institutional investors. Comparatively, 21.1% of ImmuPharma shares are held by institutional investors. 36.7% of BiVictriX Therapeutics shares are held by company insiders. Comparatively, 43.0% of ImmuPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
ImmuPharma received 266 more outperform votes than BiVictriX Therapeutics when rated by MarketBeat users.
BiVictriX Therapeutics has higher earnings, but lower revenue than ImmuPharma. BiVictriX Therapeutics is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, BiVictriX Therapeutics' average media sentiment score of 0.00 equaled ImmuPharma'saverage media sentiment score.
Summary
ImmuPharma beats BiVictriX Therapeutics on 6 of the 10 factors compared between the two stocks.
Get BiVictriX Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BiVictriX Therapeutics Competitors List
Related Companies and Tools
